Narcotic Patents (Class 514/812)
  • Patent number: 6057368
    Abstract: The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a primate suffering from substance addiction. The method includes administering to a primate an effective amount of a pharmaceutical composition including gamma vinylGABA. The present invention also provides a method of treatment of nicotine addiction by treating a patient with an effective amount of a composition including gamma vinylGABA.
    Type: Grant
    Filed: August 5, 1998
    Date of Patent: May 2, 2000
    Assignee: Brookhaven Science Associates LLC
    Inventors: Stephen L. Dewey, Jonathan D. Brodie, Charles R. Ashby, Jr.
  • Patent number: 6051564
    Abstract: The invention is to a method for the treatment of withdrawal symptoms selected from the group consisting of nausea, sweating, shaking, substance craving and hot flushes.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: April 18, 2000
    Assignee: Modus Biological Membranes Ltd.
    Inventors: Avner Shenfeld, Meir Shinitzky
  • Patent number: 6008258
    Abstract: The present invention relates to a method of treating pain in a subject having a NMDA recptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the NMDA receptor of the subject. The present invention further relates to a method of treating tolerance and physical dependence in a subject and a method of binding to a NMDA receptor.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: December 28, 1999
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Charles E. Inturrisi
  • Patent number: 6004962
    Abstract: Rapid opioid detoxification procedures are provided which include sedating a patient with a rapid-acting, safely reversible intravenous anesthetic agent having a very short full recovery period. The patient is administered an opioid antagonist while sedated and can be revived to an ambulatory condition within eight hours of initiating therapy. The described methods for detoxification can be used with dually-addicted patients who have abused opiates, such as heroin, as well as benzodiazepines. Even with these dually-addicted patients, the process is completely reversible early on in the procedure if any adverse complications arise.
    Type: Grant
    Filed: September 11, 1995
    Date of Patent: December 21, 1999
    Inventor: Lance L. Gooberman
  • Patent number: 5958896
    Abstract: Disclosed herein is a method for reducing stimulant dependencies in mammals that involves administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, such as CDP-choline.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: September 28, 1999
    Assignee: The McLean Hospital
    Inventors: Perry F. Renshaw, Scott Lukas
  • Patent number: 5952314
    Abstract: An enteral nutritional product for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: September 14, 1999
    Inventors: Stephen Joseph DeMichele, Keith Allen Garleb, John William McEwen, Martha Kay Fuller
  • Patent number: 5935975
    Abstract: A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or an agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or an agonist in an amount sufficient to at least partially block the pharmacologic effects of the drug or an agonist while there is a substantial amount of the drug or an agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or an agonist thereof.
    Type: Grant
    Filed: April 30, 1993
    Date of Patent: August 10, 1999
    Assignee: Robert J. Schaap
    Inventors: Jed R. Rose, Edward D. Levin
  • Patent number: 5925680
    Abstract: The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: July 20, 1999
    Assignee: Eli Lilly and Company
    Inventors: David R. Helton, James A. Monn, Darryle D. Schoepp, Joseph P. Tizzano
  • Patent number: 5922705
    Abstract: Methods for rapid detoxification of patients addicted to opioid narcotics are provided. The methods include administering nalmefene to induce acute withdrawal, and administering dextromethorphan with nalmefene or other opioid antagonists to reduce the patient's subjective feelings of residual withdrawal symptoms following detoxification. In one method of rapid detoxification, unconsciousness is induced by anesthetizing the patient with desflurane.
    Type: Grant
    Filed: April 13, 1998
    Date of Patent: July 13, 1999
    Assignee: Intensive Narcotic Detoxification Centers of America, LLC
    Inventor: David Lew Simon
  • Patent number: 5919760
    Abstract: The invention provides a method for treating acute and severe diarrhea such as that which accompanies chemotherapy and rapid narcotic detoxification. The method includes administering octreotide in an amount sufficient to alleviate the diarrhea without precipitating clinically significant bradycardia. In a preferred embodiment an anticholenergic is administered together with octreotide to further reduce the possibility of significant bradycardia. The invention also provides a method for rapidly detoxifying a patient addicted to narcotics. Acute and severe diarrhea is eliminated during detoxification by administering octreotide in according to the above-described method.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: July 6, 1999
    Assignee: Intensive Narcotic Detoxification Centers of America, LLC
    Inventor: David Lew Simon
  • Patent number: 5919781
    Abstract: The present invention provides a method for the treatment or prevention of substance use disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: July 6, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen Mary Seward, Christopher John Swain, Brian John Williams
  • Patent number: 5902823
    Abstract: The present invention relates to the use of forskolin and of the extracts containing it for the treatment of alcohol addiction.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: May 11, 1999
    Assignee: Indena S.p.A.
    Inventors: Paolo Morazzoni, Ezio Bombardelli
  • Patent number: 5869474
    Abstract: Ketoconazole is used for treating cocaine addiction. Mammals, including humans, that are chronically addicted to cocaine are treated with ketoconazole to decrease self-administration of the drug.
    Type: Grant
    Filed: May 16, 1997
    Date of Patent: February 9, 1999
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Nicholas E. Goeders
  • Patent number: 5861422
    Abstract: A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic effects of the drug or its other agonist while there is a substantial amount of the drug or other agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially, simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: January 19, 1999
    Assignee: Robert J. Schaap
    Inventors: Jed E. Rose, Edward D. Levin
  • Patent number: 5846974
    Abstract: This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: December 8, 1998
    Assignee: Eli Lilly and Company
    Inventors: Mary J. Kallman, Kurt Rasmussen
  • Patent number: 5843480
    Abstract: A controlled-release pharmaceutical preparation comprising diamorphine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: December 1, 1998
    Assignee: Euro-Celtique, S.A.
    Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Derek Allan Prater, Trevor John Knott, Hassan Mohammad
  • Patent number: 5834477
    Abstract: An opiate analgesic drug formulation which induces minimal respiratory dession is provided which contains a homogeneous mixture of an opiate agonist drug component and an opiate antagonist drug component in an aqueous medium, the opiate agonist component and the opiate antagonist component being present in the mixture in a molar ratio, wherein when the drug formulation is administered to a patient in an amount sufficient for the opiate agonist drug component to induce analgesia in the patient, substantially no respiratory depression is induced in the patient.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: November 10, 1998
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Robert John Mioduszewski
  • Patent number: 5824684
    Abstract: A method for treating treating drug and alcohol addiction comprising administering to a human suffering from such addiction an effective amount of an acetylcholine esterase reactivator.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: October 20, 1998
    Assignee: Synapse Pharmaceuticals International, Inc.
    Inventor: Norman Viner
  • Patent number: 5801171
    Abstract: 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine and its pharmaceutically and veterinarily acceptable salts have activity in (a) preventing or reducing dependence on, and (b) preventing or reducing tolerance or reverse tolerance to, a dependence inducing agent such as an opioid, a central nervous system depressant, a psychostimulant or nicotine.
    Type: Grant
    Filed: December 6, 1994
    Date of Patent: September 1, 1998
    Assignee: Glaxo Wellcome Inc
    Inventor: Meire Nakamura-Craig
  • Patent number: 5789411
    Abstract: Rapid opioid detoxification procedures are provided which include sedating a patient with an anesthetic agent having a short full recovery period. The patient is administered an opioid antagonist while sedated and can be revived to an ambulatory condition within eight hours of initiating therapy. The described methods for detoxification also include administering a diarrhea suppressant, such as octreotide acetate, to limit this unfortunate side effect of the detoxification.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: August 4, 1998
    Assignee: Lance L. Gooberman P. C.
    Inventors: Lance L. Gooberman, Colin Brewer
  • Patent number: 5780051
    Abstract: The present invention features methods and articles of manufacture for treating nicotine withdrawal symptoms and promoting smoking cessation. The methods and articles feature the administration of an effective amount of a nicotine substitute and monitor the presence of nicotine in the biological sample of such subject with a nicotine detection system.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: July 14, 1998
    Assignee: DynaGen, Inc.
    Inventors: Amruta R. Eswara, Neal Muni, F. Howard Schneider, Peter J. Mione
  • Patent number: 5780451
    Abstract: An enteral nutritional product for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: July 14, 1998
    Assignee: Abbott Laboratories
    Inventors: Stephen Joseph DeMichele, Keith Allen Garleb, John William McEwen, Martha Kay Fuller
  • Patent number: 5767125
    Abstract: This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of the bimodally-acting opioid agonist. The method of the present invention comprises administering to a subject an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist such as morphine and an amount of an excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of the bimodally-acting opioid agonist and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of the bimodally-acting opioid agonist.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: June 16, 1998
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: Stanley M. Crain, Ke-fei Shen
  • Patent number: 5760044
    Abstract: The present invention relates to methods for treating cocaine and amphetamine dependency. The method involves administering to the patient an effective amount of a compound having the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen and C1 to C6 alkyl;R.sup.2 is selected from the group consisting of hydrogen, methyl, and ethyl;R.sup.3 is selected from the group consisting of hydrogen, methyl, C1 to C6 alkanoyl, C3 to C6 cycloalkanoyl, and pyridinecarbonyl;Q is a bivalent alkylene moiety; andY is selected from the group consisting of a halo-(C2 to C6)-alkenyl moiety having 1 or 2 chlorine or bromine atoms attached to the ethylenic carbon, a cycloalkyl moiety, a cyano moiety, and a cyano-(C3 to C6)-alkenyl moietyor a pharmaceutically acceptable acid-addition salt thereof. Discomforting side effects can be minimized by optionally administering naltrexone, naloxone, or a mixture thereof during the early phases of treatment.
    Type: Grant
    Filed: May 16, 1996
    Date of Patent: June 2, 1998
    Inventor: Sydney Archer
  • Patent number: 5732717
    Abstract: This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
    Type: Grant
    Filed: August 12, 1996
    Date of Patent: March 31, 1998
    Assignee: Eli Lilly and Company
    Inventors: August M. Watanabe, Thomas F. Bumol, Mitchell I. Steinberg, Mary J. Kallman, Kurt Rasmussen
  • Patent number: 5726190
    Abstract: A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine, or an agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or an agonist in an amount sufficient to at least partially block the pharmacologic effects of the drug or agonist while there is a substantial amount of the drug or agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or agonist thereof.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: March 10, 1998
    Assignee: Robert J. Schaap
    Inventors: Jed E. Rose, Edward D. Levin
  • Patent number: 5703101
    Abstract: A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic effects of the drug or its other agonist. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist.
    Type: Grant
    Filed: December 11, 1995
    Date of Patent: December 30, 1997
    Assignee: Robert J. Schaap
    Inventors: Jed E. Rose, Edward D. Levin
  • Patent number: 5681578
    Abstract: A composition for relieving stress, anxiety, grief, and depression includes GABA (gamma amino butyric acid), glutamine, glycine, magnesium, passion flower, primula officinalis, and vitamin B-6.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: October 28, 1997
    Inventor: Billie J. Sahley
  • Patent number: 5661184
    Abstract: The present invention provides a method of treating substance dependence disorders using an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: August 26, 1997
    Assignee: Eli Lilly and Company
    Inventors: David R. Helton, Mary Jeanne Kallman, James A. Monn, Darryle D. Schoepp, Joseph P. Tizzano
  • Patent number: 5654281
    Abstract: Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA receptor activation, e.g., a ganglioside such as GM.sub.1 or GT.sub.1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl) -5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: August 5, 1997
    Assignee: Virginia Commonwealth University
    Inventors: David J. Mayer, Donald D. Price, Jianren Mao, John W. Lyle
  • Patent number: 5633259
    Abstract: The present invention relates to a method of using a bioassay consisting of an electrophysiological method and a cell culture system of dorsal-root ganglion (DRG) neurons to screen and identify opioids with a high potential for use as "low- or non-addictive" analgesics. Another aspect of the invention relates to a specific group of opioid alkaloids and analogues thereof identified by the bioassay of the invention for the unique ability to activate only inhibitory, but not excitatory, opioid receptor function, for use as low- or non-addictive analgesics. Another aspect of the invention relates to the specific use of etorphine or dihydroetorphine of the opioid alkaloid family as low- or non-addictive analgesics and for the treatment of opioid addiction.
    Type: Grant
    Filed: February 13, 1995
    Date of Patent: May 27, 1997
    Assignee: United Biomedical, Inc.
    Inventors: Bo-yi Qin, Xiong-qi Gong, Mao Huang, Li-Jun Sha, Chang Yi Wang
  • Patent number: 5629336
    Abstract: Compounds capable of interacting with the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor are active in preventing or reducing dependence on dependence-inducing agents such as morphine, but lack the undesirable side-effects of agents hitherto employed for this purpose.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: May 13, 1997
    Assignee: Merck, Sharp & Dohme Ltd.
    Inventor: Peter H. Hutson
  • Patent number: 5622713
    Abstract: A method for accumulating drugs or other chemicals within synthetic, lipid-like vesicles by means of a pH gradient imposed on the vesicles just prior to use is described. The method is suited for accumulating molecules with basic or acid moieties which are permeable to the vesicles membranes in their uncharged form and for molecules that contain charge moieties that are hydrophobic ions and can therefore cross the vesicle membranes in their charged form.The method is advantageous over prior art methods for encapsulating biologically active materials within vesicles in that it achieves very high degrees of loading with simple procedures that are economical and require little technical expertise, furthermore kits which can be stored for prolonged periods prior to use without impairment of the capacity to achieve drug accumulation are described.
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: April 22, 1997
    Assignee: The Regents of the University of California
    Inventor: Rolf J. Mehlhorn
  • Patent number: 5616585
    Abstract: Racemic or optically active pyrido[1,2-a]pyrazine derivatives of the formula ##STR1## wherein X is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals are useful in the treatment of abuse of and/or addiction to such substances as narcotics, alcohol and nicotine.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: April 1, 1997
    Assignee: Pfizer Inc.
    Inventor: Gene M. Bright
  • Patent number: 5616575
    Abstract: Ibogaine analogs are provided, which are phenyl-substituted-hexahydroazepino[4,5-b]indoles useful to treat cocaine addiction and the use of other addictive substances.
    Type: Grant
    Filed: December 4, 1995
    Date of Patent: April 1, 1997
    Assignees: Regents of the University of Minnesota, University of Miami
    Inventors: S. Mbua N. Efange, Deborah C. Mash
  • Patent number: 5594030
    Abstract: Controlled release pharmaceutical compositions administrable by oral route, containing as the active principle at least one salt of the gamma hydroxy butyric acid with a pharmaceutically acceptable cation, for the treatment of alcoholism, opium like substances addiction, heroin addiction, food and nicotine addiction, depressive and anxious states, composed by:a) a nucleus in the form of granules and tablets comprising an active principle dispersed in a particular cellulosic matrix; and optionally by:b) a filming protection of the nucleus.
    Type: Grant
    Filed: July 21, 1994
    Date of Patent: January 14, 1997
    Assignee: Laboratorio Farmaceutico C.T. S.r.l.
    Inventors: Ubaldo Conte, Aldo La Manna, Giuseppe Tessitore
  • Patent number: 5591738
    Abstract: A method of treating a chemical dependency disorder, an abuse syndrome or a combination thereof in a mammal in need thereof, which entails administering, to a mammal in need thereof, an amount of a .beta.-carboline alkaloid, hydrolyzable derivative thereof or pharmaceutically-acceptable salt thereof effective to treat said chemical dependency disorder, abuse syndrome or a combination thereof in the mammal.
    Type: Grant
    Filed: October 14, 1994
    Date of Patent: January 7, 1997
    Assignee: NDA International, Inc.
    Inventor: Howard S. Lotsof
  • Patent number: 5578645
    Abstract: Methods and compositions for treating acute or chronic pain in a mammal comprising administering a therapeutically effective amount of an analgesic solution comprising at least one branched chain amino acid selected from the group consisting of leucine, isoleucine, and valine, or administering a therapeutically effective amount of an analgesic solution comprising an analgesic agent selected from the group consisting of an opioid, an agonistic-antagonistic agent, and an anti-inflammatory agent, and at least one branched chain amino acid selected from the group consisting of leucine, isoleucine, and valine. A method and composition for treating addiction to narcotic drugs comprises administering a therapeutically effective amount of a solution comprising methadone and at least one branched chain amino acid selected from the group consisting of leucine, isoleucine, and valine.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 26, 1996
    Assignee: Aminotek Sciences, Inc.
    Inventors: Jeffrey Askanazi, David P. Katz, Tuula Manner
  • Patent number: 5574052
    Abstract: A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic effects of the drug or its other agonist while there is a substantial amount of the drug or other agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: November 12, 1996
    Assignee: Robert J. Schaap
    Inventors: Jed E. Rose, Edward D. Levin
  • Patent number: 5565455
    Abstract: A method for relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or substances of abuse which comprises administering to a patient in need thereof an effective amount of a bisphenylalkylpiperazinde derivative, wherein said withdrawal syndrome comprises at least one of the symptoms selected from the group consisting of sleep disturbance, mood disturbance, and craving for the drug or substance of abuse.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: October 15, 1996
    Assignee: Pharmacia AB
    Inventors: Anders Bjork, Gunnar Andersson
  • Patent number: 5556837
    Abstract: The present invention is broadly directed to treatment of an addictive disease or disorder. In particular, the invention relates to inhibiting or reversing the biochemical and neurophysiological changes that correlate with behavioral changes of addictive diseases or disorders. The method of the invention comprises administering to a subject suspected of suffering from an addictive disease or disorder an amount of brain-derived factor (BDNF) or neurotrophin-4 (NT-4), or both, effective to reverse behavioral changes that are associated with the addictive disease or disorder. In a specific Example, administration of BDNF or NT-4 inhibits or reverses increased expression of tyrosine hydroxylase and glial ibrillary acidic protein in the ventral tegmental area of the brain, and inhibits or reverses increased levels of cyclic-AMP-dependent protein kinase activity in the nucleus accumbens.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: September 17, 1996
    Assignees: Regeneron Pharmaceuticals Inc., Yale University
    Inventors: Eric J. Nestler, Melissa T. Berhow, Dana Beitner-Johnson, David S. Russell, Ronald M. Lindsay
  • Patent number: 5556838
    Abstract: Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM.sub.1 or GT.sub.1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: September 17, 1996
    Assignee: Virginia Commonwealth University
    Inventors: David J. Mayer, Donald D. Price, Jianren Mao, John W. Lyle
  • Patent number: 5547956
    Abstract: The invention relates to a pharmaceutical composition and a method for treating drug addicts' withdrawal syndrome and detoxifying addicts. The pharmaceutical composition comprises aconitane derivative of formulas I, II, their inorganic acid salts or mixtures thereof, and tetrahydroprotoberberine derivatives of formula II. The method of treatment comprises administering the pharmaceutical composition to drug addicts. The pharmaceutical composition of the present invention produces no drug dependence, excellent effects, fast action and low side-effects.
    Type: Grant
    Filed: September 22, 1993
    Date of Patent: August 20, 1996
    Assignee: Yueqian Qu
    Inventors: Yueqian Qu, Peng Qu
  • Patent number: 5538959
    Abstract: A magnesium-containing analgesic composition used for treating migraine headaches and methods for using the same are described herein. The composition comprises an analgesic, a magnesium salt and an effervescing agent and is admixed with or dissolved in water prior to ingestion. The symptoms of migraine headache intended to be alleviated include nausea, unilateral pain, dizziness, pulsatile pain, worsening of pain by light physical activity, photophobia and phonophobia.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: July 23, 1996
    Inventor: Alexander Mauskop
  • Patent number: 5536503
    Abstract: A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems and kits containing the drug delivery systems.
    Type: Grant
    Filed: April 3, 1995
    Date of Patent: July 16, 1996
    Assignee: DynaGen, Inc.
    Inventors: Judith P. Kitchell, Indu A. Muni, Yvonne N. Boyer
  • Patent number: 5534492
    Abstract: Muramyl peptide compounds are useful in the treatment of toxicity, particularly when this condition results from alcohol, hypnotics or sedatives, anaesthetics, opioids or drug abuse generally. The muramyl peptide compound may be of either of general formulae I and II: ##STR1## Preferred compounds include prototype MDP, muroctasin, MTP-PE, murabutide, t-MDP, N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-glutamic acid (GMDP-A).
    Type: Grant
    Filed: January 3, 1995
    Date of Patent: July 9, 1996
    Assignee: Peptech (UK) Limited
    Inventors: Roger Aston, Igor E. Kovalev
  • Patent number: 5512578
    Abstract: This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side effects caused by the chronic administration of said bimodally-acting opioid agonists comprising the co-administration of a bimodally-acting opioid agonist which activates both inhibitory and excitatory opioid receptor-mediated functions of neurons in the nociceptive (pain) pathways of the nervous system and an opioid receptor antagonist which selectively inactivates excitatory opioid receptor-mediated side effects. This invention also relates to a method of using excitatory opioid receptor antagonists alone to block the undesirable excitatory side effects of endogenous bimodally-acting opioid agonists which may be markedly elevated during chronic pain.
    Type: Grant
    Filed: July 19, 1994
    Date of Patent: April 30, 1996
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: Stanley M. Crain, Ke-Fei Shen
  • Patent number: 5500433
    Abstract: The present invention is directed to a new class of piperidinyl medicinal agents which are useful for treating drug abuse.
    Type: Grant
    Filed: January 10, 1995
    Date of Patent: March 19, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Albert A. Carr, Richard C. Dage, John E. Koerner, Tung Li, Francis P. Miller, Thaddeus R. Nieduzak, Mark W. Dudley, . Christopher J. Schmidt, Robert A. Frank
  • Patent number: 5486362
    Abstract: A drug delivery system useful in treating an individual for a drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems.
    Type: Grant
    Filed: October 21, 1993
    Date of Patent: January 23, 1996
    Assignee: DynaGen, Inc.
    Inventors: Judith P. Kitchell, Indu A. Muni, Yvonne N. Boyer
  • Patent number: RE36547
    Abstract: This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side effects caused by the chronic administration of said bimodally-acting opioid agonists comprising the co-administration of a bimodally-acting opioid agonist which activates both inhibitory and excitatory opioid receptor-mediated functions of neurons in the nociceptive (pain) pathways of the nervous system and an opioid receptor antagonist which selectively inactivates excitatory opioid receptor-mediated side effects. This invention also relates to a method of using excitatory opioid receptor antagonists alone to block the undesirable excitatory side effects of endogenous bimodally-acting opioid agonists which may be markedly elevated during chronic pain.
    Type: Grant
    Filed: January 13, 1996
    Date of Patent: February 1, 2000
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Stanley M. Crain, Ke-Fei Shen